Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 7
- 主要终点
- Differences in concentrations of individual volatile biomarkers and combinations of biomarkers in breath samples obtained from persons with and without P. aeruginosa lung infections
研究概览
简要总结
The study is a breath biomarker validation study. It is anticipated that 300 patients with cystic fibrosis (CF) from 5 clinical sites in the USA will be enrolled. The study is funded by the US NIH and the US Cystic Fibrosis Foundation. Enrollment commenced in May 2019. Sputum, induced sputum, and oropharyngeal swabs will be collected and evaluated at each clinic as part of standard clinical practice. Excess sputum will be sent to Children's Colorado Hospital for molecular analysis. No swabs will be sent anywhere (other than the clinic from which they originate). Breath samples will be taken from all study participants.
详细描述
AIM 1: Refine and validate volatile biomarkers in the breath of adult and pediatric CF patients for detecting established P. aeruginosa lung infections. For each expectorating subject (n ≥ 288; 5 centers), the diagnostic accuracy of the volatile biomarker panel will be tested, with sputum culture as the standard.
AIM 2: Quantify intra-subject breath variability of the target pediatric population. We will collect longitudinal breath samples for two years from P. aeruginosa-negative subjects (n ≥ 58; ~60% non-expectorating) at 4 pediatric CF clinical centers. We will measure intra-subject variance in the breath signatures of expectorating and non-expectorating subjects, with the latter being the target population for the clinical trial. Two to 8 breath samples will be collected per patient.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aim 1, Cross-Sectional
- •IInclusion Criteria:
- •Male or female, ages 8 years and older
- •Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations
- •@ BC Children's Hospital only- Non-expectorators are eligible if having a clinically indicated OP swab.
- •FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted for subjects undergoing sputum induction
- •Either P. aeruginosa (Pa) negative or chronically infected with P. aeruginosa (Pa positive) as defined below:
- •a. P. aeruginosa negative: must meet one of the following criteria: i: No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures, OR ii: No history of Pa positive airway cultures (sputum, OP, Bronchoalveolar lavage) b. P. aeruginosa positive i: Over 50% of cultures positive and at least 2 cultures positive for Pa in previous 18 months
- •Willing to participate in and comply with the study procedures and willingness of the subject, parent or legally authorized representative to provide written informed consent.
- •Exclusion criteria:
- •Age < 8 years
- •Intermittently infected with Pa
- •FEV1 < 30%
- •History of lung transplant
- •Presence of a condition or abnormality that in the opinion of the Principal Investigator would compromise the safety of the subject or the quality of the data.
- •Aim 2, Longitudinal
- •Inclusion Criteria, Expectorating Cohort (n=48):
- •Male or female, ages 8-16 years
- •Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations
- •@ BC Children's Hospital only- Non-expectorators are eligible if having a clinically indicated OP swab.
- •FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted for subjects undergoing sputum induction
- •P. aeruginosa negative, based on one of the following criteria:
- •No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures
- •No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage)
- •Willing to participate in and comply with the study procedures and willingness of the subject, parent or legally authorized representative to provide written informed consent.
- •Exclusion criteria:
- •Age < 8 years
- •Intermittently or chronically infected with Pa
- •Unable to expectorate sputum or undergo sputum induction
- •FEV1 < 30%
- •History of lung transplant
- •Presence of a condition or abnormality that in the opinion of the Principal Investigator would compromise the safety of the subject or the quality of the data.
- •Inclusion Criteria, Non-Expectorating Cohort (n=10):
- •Male or female, ages 3-8 years
- •Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations
- •Unable to expectorate sputum
- •P. aeruginosa negative, based on one of the following criteria:
- •No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures
- •No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage)
- •Willing to participate in and comply with the study procedures and willingness of the subject, parent or legally authorized representative to provide written informed consent.
- •Exclusion criteria:
- •Age < 3 years
- •Intermittently or chronically infected with Pa
- •FEV1 < 30%
- •History of lung transplant
- •Presence of a condition or abnormality that in the opinion of the Principal Investigator would compromise the safety of the subject or the quality of the data.
排除标准
- 未提供
结局指标
主要结局
Differences in concentrations of individual volatile biomarkers and combinations of biomarkers in breath samples obtained from persons with and without P. aeruginosa lung infections
时间窗: Enrollment thru 2023. Last Longitudinal Study Visit will be 24 months after last AIM 2 enrollment
Measured using comprehensive two-dimensional gas chromatography of exhaled breath compared to sputum culture (gold standard)
次要结局
- Intra-subject changes in concentrations of individual volatile biomarkers and combinations of biomarkers in breath samples(Thru end of 2025)
研究者
Jane Hill, PhD
Associate Professor
University of British Columbia